Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06028633 | Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients | not yet recruiting | Phase 2 | 28 | Peking University First HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06032728 | Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment | not yet recruiting | N/A | 488 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Sep 13, 2023 |
| clinicaltrials |
| NCT06035133 | Treatment of Low Locally Advanced Rectal Cancer With Radiotherapy Removal TNT Plus Neoadjuvant Therapy | not yet recruiting | N/A | 213 | Tang-Du HospitalOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT03865277 | Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging(INDIRA-MISO) | not yet recruiting | Phase 2 | 276 | Technische Universität DresdenOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06029465 | Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 8, 2023 | clinicaltrials |
| NCT06029478 | Understanding Engagement Trends in Chondrosarcoma Clinical Trials | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Sep 8, 2023 | clinicaltrials |
| NCT06026501 | A Phase Ib/II Clinical Trial of PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor | not yet recruiting | Phase 1 / Phase 2 | 120 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Sep 7, 2023 | clinicaltrials |
| NCT06023277 | A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 40 | Jacinto Convit World Organization Inc.OTHER | 2 | Sep 5, 2023 | clinicaltrials |
| NCT06022341 | MultiOmic characteriZation of Acute Myeloid Leukemia Evolving From myelopRoliferative Neoplasm to Identify New Targeted Therapeutic Strategies(MOZART) | not yet recruiting | N/A | 120 | University Hospital, AngersOTHER_GOV | 0 | Sep 1, 2023 | clinicaltrials |
| NCT06014944 | Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody(PMMR/MSS) | not yet recruiting | Phase 2 | 30 | Changhai HospitalOTHER | 0 | Aug 31, 2023 | clinicaltrials |
| NCT06017063 | Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields(COCOON) | not yet recruiting | N/A | 275 | University Hospital TuebingenOTHER | 0 | Aug 30, 2023 | clinicaltrials |
| NCT05730595 | Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer(FLORA-01) | not yet recruiting | N/A | 550 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT06015113 | Efficacy and Safety of Disitamab Vedotin Plus Pyrotinib or Naratinib in HER2-positive Breast Cancer Patients With Brain Metastasis | not yet recruiting | N/A | 20 | Xi'an International Medical Center HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT06016413 | Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck | not yet recruiting | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05914610 | Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer | not yet recruiting | Phase 3 | 100 | Fujian Medical UniversityOTHER | 0 | Aug 25, 2023 | clinicaltrials |
| NCT06009029 | SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study) | not yet recruiting | Phase 2 | 96 | Peking University Third HospitalOTHER | 0 | Aug 24, 2023 | clinicaltrials |
| NCT06009510 | Exploring Engagement Dynamics Among Individuals Impacted by Bladder Cancer | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Aug 24, 2023 | clinicaltrials |
| NCT06009549 | A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05985707 | KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma | not yet recruiting | Phase 2 | 80 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05998798 | Revealing Engagement Patterns Among Endometrial Cancer Patients | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05998811 | Insights Into Participating in Studies for Uterine Cancer | not yet recruiting | — | 500 | Power Life Sciences Inc.INDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05998993 | Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)(CULTRO) | not yet recruiting | N/A | 35 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05998122 | Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study | not yet recruiting | Phase 2 | 45 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05993858 | Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC(PC-1) | not yet recruiting | Phase 2 | 33 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05990127 | A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer | not yet recruiting | Phase 3 | 642 | AkesoINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05788107 | Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma | not yet recruiting | Phase 1 | 30 | Shanghai Henlius BiotechINDUSTRY | 0 | Aug 9, 2023 | clinicaltrials |
| NCT05983094 | Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer | not yet recruiting | Phase 2 | 181 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05980208 | A Real-world Study of Inetetamab for First-line Treatment of MBC | not yet recruiting | — | 150 | Hunan Cancer HospitalOTHER | 0 | Aug 8, 2023 | clinicaltrials |
| NCT05978882 | Feasibility Study of Sentinel Navigation Surgery in Early Gastric Cancer Using Fluorescence (SENORITA4) | not yet recruiting | N/A | 203 | National Cancer Center, KoreaOTHER_GOV | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05979220 | Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy | not yet recruiting | Phase 2 | 178 | Shuangyue LiuOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05976568 | A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 / Phase 3 | 668 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05971628 | Resection And Partial LIver Transplantation With Delayed Hepatectomy for Hepatocellular Carcinoma(RAPID-HCC) | not yet recruiting | N/A | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05969847 | Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer(TRACE-LE) | not yet recruiting | Phase 2 | 72 | 池畔OTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05970627 | Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | not yet recruiting | Phase 2 | 30 | Yu jirenOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05970900 | Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST(PIRKER) | not yet recruiting | Phase 3 | 23 | Fujian Medical University Union HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05959226 | Effect of Exercise and Enteral Nutrition on Survival(ENERGY) | not yet recruiting | N/A | 960 | The First Hospital of Jilin UniversityOTHER | 0 | Jul 25, 2023 | clinicaltrials |
| NCT05862610 | The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC | not yet recruiting | Phase 2 | 150 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 24, 2023 | clinicaltrials |
| NCT05917821 | New Antigens Against Glioblastoma(INAAG) | not yet recruiting | — | 120 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Jul 24, 2023 | clinicaltrials |
| NCT05794659 | Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer(Cornerstone4) | not yet recruiting | Phase 2 | 98 | Aston Sci. Inc.INDUSTRY | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05954117 | Chemotherapy in the Context of Esophageal and Gastroesophageal Junction Cancer Cachexia(CHIFMEOE) | not yet recruiting | N/A | 60 | University Hospital, Clermont-FerrandOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05354674 | Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis | not yet recruiting | — | 302 | Fudan UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05940116 | A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 322 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05941169 | Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy(PrimerX) | not yet recruiting | N/A | 750 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 0 | Jul 12, 2023 | clinicaltrials |
| NCT05934058 | Genomic and Dietary Aspects in Gastric Cancer Risk(GenoStoP) | not yet recruiting | — | 383,980 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05875649 | A Multicenter Prospective Cohort Study Study of CLAG Regimen in Acute Myeloid Leukemia Patients With First-induction Failure(CLAG) | not yet recruiting | — | 137 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05931055 | The Effectiveness of Liquid Biopsy in Differential Diagnosis and Early Screening of Epithelial Ovarian Cancer | not yet recruiting | — | 1,000 | Peking Union Medical College HospitalOTHER | 0 | Jul 5, 2023 | clinicaltrials |
| NCT05931757 | A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL | not yet recruiting | Phase 2 | 22 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05802654 | Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer(USBRT-1) | not yet recruiting | N/A | 100 | Peking University Third HospitalOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05840042 | Epidemiology and Risk Factors of Uterine Fibroids in China | not yet recruiting | — | 20,000 | Shixuan WangOTHER | 0 | Jun 22, 2023 | clinicaltrials |
| NCT05909423 | Combining Intratumoral Flu Vaccine and Systemic Pembrolizumab in Patients With Early pMMR Colorectal Cancer(FLU-IMMUNE) | not yet recruiting | Phase 2 | 21 | Zealand University HospitalOTHER | 1 | Jun 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 13, 2023source: clinicaltrials